<DOC>
	<DOCNO>NCT03091257</DOCNO>
	<brief_summary>This research study study target therapy possible treatment multiple myeloma . The name study drug involve study : - Trametinib - Dabrafenib</brief_summary>
	<brief_title>A Study Dabrafenib and/or Trametinib Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description>This research study Pilot Study , first time investigator examine study drug disease . `` Investigational '' mean combination drug study . It also mean FDA ( U.S. Food Drug Administration ) approve drug type cancer . The FDA approve Trametinib Dabrafenib specific disease approve us . Some cancer change ( mutation ) gene call BRAF gene , call KRAS NRAS . These three gene tell body make protein call BRAF , KRAS , NRAS , respectively , involve sending signal cell lead cell growth . Certain mutation three gene cause change protein increase growth spread cancer cell . Dabrafenib trametinib work prevent alter protein work send signal cancer cell , thereby may block growth spread cancer cell people cancer BRAF , KRAS , NRAS gene mutation . Dabrafenib trametinib use treatment cancer research study , information research study suggest agent may help kill multiple myeloma cell . Dabrafenib trametinib , investigate research study may may kill myeloma cell effectively . We would like see drug give alone combination safely effectively kill cancer cell .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Participants must confirm diagnosis multiple myeloma define follow criterion : Monoclonal plasma cell bone marrow great equal 10 % and/or presence biopsyproven plasmacytoma Monoclonal protein present serum and/or urine Measurable disease define follow : IgG multiple myeloma : Serum monoclonal paraprotein ( Mprotein ) level great equal 0.5 g/dL urine Mprotein level great equal 200 mg/24 hour IgA multiple myeloma : Serum Mprotein level great equal 0.5 g/dL urine Mprotein level great equal 200 mg/24 hour IgD multiple myeloma : Serum Mprotein level great equal 0.5 g/dL urine Mprotein level great equal 200 mg/24 hour Light chain multiple myeloma : Serum immunoglobulin free light chain ≥ 10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio Participants must myeloma measurable either serum urine evaluation monoclonal component assay serum free light chain . Measurable disease define one following : serum Mprotein ≥0.5 g/dL , urine Mprotein ≥200 mg/24 h , and/or serum FLC assay : involve FLC level ≥10 mg/dL abnormal serum FLC ratio . Relapsed disease least 2 line therapy Age ≥ 18 year year time signing informed consent form . ECOG performance status ≤2 ( Karnofsky ≥60 % , see Appendix A ) Participants must sufficient organ marrow function define : Participants platelet level ≥50,000/mm3 , within 21 day initiation protocol therapy patient &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count ≥30,000/mm3 participant &gt; 50 % bone marrow nucleate cell plasma cell . Transfusion within 7 day screen allow meet platelet eligibility criterion . Participants absolute neutrophil count ( ANC ) ≥1000/mm3 , within 21 day initiation protocol therapy . Growth factor within 7 day screen allow meet ANC eligibility criterion . Participants hemoglobin level ≥ 8 g/dL , within 21 day initiation protocol therapy . Transfusion may use meet hemoglobin eligibility criterion . Hepatic impairment , define total bilirubin ≤ 1.5 x institutional ULN ( patient benign hyperbilirubinemia ( e.g. , Gilbert 's syndrome ) eligible . ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 2 x institutional ULN , within 21 day initiation protocol therapy . PT/INR PTT ≤ 1.3 x institutional upper limit normal . Subjects receive anticoagulation treatment may allow participate INR establish within therapeutic range prior alternate assignment . Total bilirubin ≤ 1.5 × institutional upper limit normal , except subject know Gilbert 's syndrome . Creatinine ≤ 2.0 mg/dl Serum calcium albuminadjusted serum calcium ≥ 2.0 mmol/L ( 8.0 mg/dL ) ≤ 2.9 mmol/L ( 11.5 mg/dL ) Left Ventricular Ejection Fraction ( LVEF ) ≥ LLN ECHO . Abbreviations : ALT = alanine transaminase ; ANC = absolute neutrophil count ; AST = aspartate aminotransferase ; INR = international normalized ratio ; LLN = low limit normal ; PT = prothrombin time ; PTT = partial thromboplastin time ; Harboring mutation BRAF oncogene KRAS NRAS oncogene Women childbearing potential must negative serum pregnancy test within 14 day prior enrollment agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation 4 month last dose study treatment . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A pregnancy test require female participant age 60 postmenopausal least 24 month . Male participant , even surgically sterilize ( i.e. , status post vasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Ability understand willingness sign write informed consent document . Participant must able swallow pill retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Prior treatment BRAF inhibitor MEK inhibitor . Treatment localize radiotherapy exclusion criterion interval least two week end radiotherapy initiation protocol therapy observe . Primary amyloidosis ( AL ) myeloma complicate amyloidosis Nonsecretory multiple myeloma base upon standard Mcomponent criterion ( ie , measurable serum/urine Mcomponent ) unless baseline serum free light chain level elevate . Patients plasmacytomas biopsy proven know mutation may include long evaluable disease image . Participants receive investigational agent within 2 week start trial throughout duration trial . Participants receive anticancer treatment ( chemotherapy , immunotherapy , biologic therapy , vaccine therapy , investigational treatment ) within 3 week prior first dose dabrafenib trametinib . Participants receive proteasome inhibitor immunomodulatory drug ( imid ) , chemotherapy without delayed toxicity within 2 week prior first dose dabrafenib trametinib . Treatment localize radiotherapy exclusion criterion interval least two week end radiotherapy initiation protocol therapy observe . Current use prohibit medication describe Section 6.4 . Participants platelet level &lt; 50,000/mm3 , within 21 day initiation protocol therapy patient &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/mm3 participant &gt; 50 % bone marrow nucleate cell plasma cell . Transfusion within 7 day screen allow meet platelet eligibility criterion . Participants absolute neutrophil count ( ANC ) &lt; 1000/mm3 , within 21 day initiation protocol therapy . Growth factor within 7 day screen allow meet ANC eligibility criterion . Participants hemoglobin level &lt; 8 g/dL , within 21 day initiation protocol therapy . Transfusion may use meet hemoglobin eligibility criterion . Hepatic impairment , define total bilirubin &gt; 1.5 x institutional ULN ( patient benign hyperbilirubinemia ( e.g. , Gilbert 's syndrome ) eligible . ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &gt; 2 x institutional ULN , within 21 day initiation protocol therapy . Renal insufficiency , define serum creatinine &gt; 2.0 mg/dL . Participant myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class II , III IV heart failure ( see Appendix G ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality , treatment refractory hypertension define blood pressure systolic &gt; 140mmHg and/ diastolic &gt; 90 mmHg control antihypertensive therapy . Prior study entry , ECG abnormality screen must document investigator medically relevant . A history evidence cardiovascular risk include follow : A QT interval correct heart rate use Bazett 's formula ( QTcB ; Appendix E ) ≥ 480 msec ; A history evidence current clinically significant uncontrolled arrhythmia ; Clarification : Subjects atrial fibrillation control &gt; 30 day prior dose eligible . A history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior alternate assignment . A history evidence current ≥ Class II congestive heart failure define New York Heart Association ( NYHA ) guideline ( Appendix G ) ; Patients intracardiac defibrillator ; Abnormal cardiac valve morphology ( ≥grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; Any serious unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure . A history Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV and/or HCV permit . Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy subject indolent second malignancy . Female participant pregnant breastfeeding . Pregnant woman exclude study dabrafenib , trametinib may teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother study drug , breastfeed discontinue mother treat study drug . Dabrafenib teratogenic embryotoxic rat dose three time great human exposure recommend clinical dose . A history current evidence retinal vein occlusion ( RVO ) History interstitial lung disease pneumonitis Patients know human immunodeficiency virus ( HIV ) combination antiretroviral therapy ineligible potential pharmacokinetic interaction dabrafenib trametinib . In addition , participant increase risk lethal infection treat marrowsuppressive therapy . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>